There are currently 10 active clinical trials seeking participants for Gout research studies. The states with the highest number of trials for Gout participants are Florida, California, Texas and North Carolina.
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
NCT06846515
Recruiting
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/11/2025
Locations: Arthrosi Investigative Site (620), Birmingham, Alabama +77 locations
Conditions: Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
Register for Updates
Dose Response of Exercise for Arthritis Management
NCT06880653
Recruiting
The purpose of the study is to see examine the effects of 3 different levels of physical activity (45 minutes/week, 90 minutes/week, or 150 minutes/week) on arthritis symptoms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: University of South Carolina, Columbia, South Carolina
Conditions: Arthritis, Rheumatoid Arthritis (RA), Gout, Fibromyalgia (FM), Osteoarthritis, Lupus Erythematosus, Systemic
Register for Updates
Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
NCT05658575
Recruiting
The purpose of this trial is to investigate the efficacy and safety of dapansutrile (OLT1177®) tablets in subjects with an acute gout flare.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/02/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +33 locations
Conditions: Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis, Gout, Arthritis, Joint Pain
Register for Updates
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
NCT04875702
Recruiting
The TRUST study is a randomized, controlled multicenter study to evaluate the management of gout by comparing two commonly used treatment strategies for gout (TTT vs TTASx) to determine the most beneficial for a patient-centered gout outcomes, as well as relevant cardiovascular-metabolic-renal endpoints.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
09/26/2024
Locations: The University of Alabama at Birmingham, South Birmingham, Alabama +6 locations
Conditions: Gout
Register for Updates
Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout
NCT05665699
Recruiting
D-0120 is being tested in combination with Allopurinol in adult subjects with Gout.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/14/2024
Locations: Study Center, Birmingham, Alabama +20 locations
Conditions: Gout
Register for Updates
Improving Gout Care After an ED Visit
NCT06534554
Recruiting
The prevalence of gout has been steadily increasing over several decades and is correlated with the rising burden of obesity, chronic cardiac and renal disease; all conditions overrepresented in the Southeastern U.S. - particularly in African Americans. Through a novel post-emergency department visit intervention, we aim to improve the care patients with gout receive, both during acute exacerbations and long-term. A secondary goal of the project is to concurrently enhance participation of minori... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/30/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Gout
Register for Updates
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers
NCT06258213
Recruiting
A randomized, double-blind, placebo-controlled, dose-escalation study will be conducted in healthy volunteers. This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ABP-745 following single (Part 1) and multiple (Part 2) oral doses.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/05/2024
Locations: Worldwide Clinical Trials, San Antonio, Texas
Conditions: Gout
Register for Updates
PatientSpot Formerly Known as ArthritisPower
NCT03840928
Recruiting
Patient Power is a patient research network and database (registry) to collect prospective information about demographics, self-reported diagnoses and medications, and willingness to participate in research from participants with rheumatoid arthritis (RA), spondyloarthritis (SpA), other musculoskeletal conditions, chronic neurological conditions like migraine, chronic pulmonary conditions like Chronic Obstructive Pulmonary Disease (COPD), asthma, autoimmune dermatological conditions such as psor... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
12/12/2023
Locations: Global Healthy Living Foundation, Upper Nyack, New York
Conditions: Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Register for Updates
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
NCT05586971
Recruiting
The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/17/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama +123 locations
Conditions: Gout, Hyperuricemia, Gout Flare, Tophi
Register for Updates
Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients
NCT05586958
Recruiting
The aim of this 6-month randomized multi-regional double-blind parallel group placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
08/24/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama +36 locations
Conditions: Gout, Hyperuricemia, Gout Flare, Tophi
Register for Updates